Jiangsu Nhwa Pharmaceutical Co Ltd (002262) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jiangsu Nhwa Pharmaceutical Co Ltd (002262) has a cash flow conversion efficiency ratio of 0.053x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥425.83 Million ≈ $62.31 Million USD) by net assets (CN¥8.08 Billion ≈ $1.18 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Jiangsu Nhwa Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how Jiangsu Nhwa Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Jiangsu Nhwa Pharmaceutical Co Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Jiangsu Nhwa Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jiangsu Nhwa Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Enaex S.A
SN:ENAEX
|
0.103x |
|
Shanghai Zhonggu Logistics Co Ltd
SHG:603565
|
0.064x |
|
FangDa Carbon New Material Co Ltd
SHG:600516
|
-0.012x |
|
YUNDA Holding Co Ltd
SHE:002120
|
0.036x |
|
LivaNova PLC
NASDAQ:LIVN
|
0.074x |
|
Sprott Inc.
TO:SII
|
0.144x |
|
Huber+suhner AG
SW:HUBN
|
0.100x |
|
China Petroleum Engineering Corp
SHG:600339
|
-0.077x |
Annual Cash Flow Conversion Efficiency for Jiangsu Nhwa Pharmaceutical Co Ltd (2005–2024)
The table below shows the annual cash flow conversion efficiency of Jiangsu Nhwa Pharmaceutical Co Ltd from 2005 to 2024. For the full company profile with market capitalisation and key ratios, see 002262 company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥7.27 Billion ≈ $1.06 Billion |
CN¥916.13 Million ≈ $134.06 Million |
0.126x | -23.15% |
| 2023-12-31 | CN¥6.41 Billion ≈ $938.00 Million |
CN¥1.05 Billion ≈ $153.73 Million |
0.164x | +6.30% |
| 2022-12-31 | CN¥5.58 Billion ≈ $817.23 Million |
CN¥861.02 Million ≈ $125.99 Million |
0.154x | +7.83% |
| 2021-12-31 | CN¥4.90 Billion ≈ $717.57 Million |
CN¥701.12 Million ≈ $102.60 Million |
0.143x | -52.98% |
| 2020-12-31 | CN¥4.11 Billion ≈ $600.76 Million |
CN¥1.25 Billion ≈ $182.67 Million |
0.304x | +258.24% |
| 2019-12-31 | CN¥3.60 Billion ≈ $527.50 Million |
CN¥305.97 Million ≈ $44.77 Million |
0.085x | -37.99% |
| 2018-12-31 | CN¥2.96 Billion ≈ $432.48 Million |
CN¥404.52 Million ≈ $59.19 Million |
0.137x | -25.53% |
| 2017-12-31 | CN¥2.46 Billion ≈ $360.17 Million |
CN¥452.35 Million ≈ $66.19 Million |
0.184x | +40.84% |
| 2016-12-31 | CN¥2.12 Billion ≈ $310.80 Million |
CN¥277.14 Million ≈ $40.55 Million |
0.130x | +16.75% |
| 2015-12-31 | CN¥1.83 Billion ≈ $267.39 Million |
CN¥204.24 Million ≈ $29.89 Million |
0.112x | -26.13% |
| 2014-12-31 | CN¥1.06 Billion ≈ $154.97 Million |
CN¥160.24 Million ≈ $23.45 Million |
0.151x | -34.89% |
| 2013-12-31 | CN¥836.21 Million ≈ $122.36 Million |
CN¥194.33 Million ≈ $28.44 Million |
0.232x | +2.88% |
| 2012-12-31 | CN¥682.44 Million ≈ $99.86 Million |
CN¥154.16 Million ≈ $22.56 Million |
0.226x | +54.92% |
| 2011-12-31 | CN¥556.01 Million ≈ $81.36 Million |
CN¥81.08 Million ≈ $11.86 Million |
0.146x | +9.15% |
| 2010-12-31 | CN¥462.56 Million ≈ $67.69 Million |
CN¥61.79 Million ≈ $9.04 Million |
0.134x | -13.66% |
| 2009-12-31 | CN¥396.00 Million ≈ $57.95 Million |
CN¥61.27 Million ≈ $8.97 Million |
0.155x | +14.38% |
| 2008-12-31 | CN¥343.75 Million ≈ $50.30 Million |
CN¥46.50 Million ≈ $6.80 Million |
0.135x | -57.54% |
| 2007-12-31 | CN¥152.39 Million ≈ $22.30 Million |
CN¥48.55 Million ≈ $7.10 Million |
0.319x | +26.12% |
| 2006-12-31 | CN¥122.67 Million ≈ $17.95 Million |
CN¥30.99 Million ≈ $4.53 Million |
0.253x | +259.29% |
| 2005-12-31 | CN¥125.74 Million ≈ $18.40 Million |
CN¥8.84 Million ≈ $1.29 Million |
0.070x | -- |
About Jiangsu Nhwa Pharmaceutical Co Ltd
Jiangsu Nhwa Pharmaceutical Co., LTD engages in production, marketing, and services related to central nervous system drugs in China. The company offers Duloxetine Hcl, Risperidone, Ziprasidone Hcl, Etomidate Fat Emulsion, Gabapentin, Zaleplon, etc., as well as Iptakalim, an anti-hypertension drug. It also provides penehyquinac acid hydrochloride injection, sufentanil citrate injection, oxeridine… Read more